Exparel generic competition status 2026?

Exparel, an extended-release liposomal bupivacaine injectable suspension, faces no generic competition currently and none are projected for 2026 [1]. This is due to patent protections that extend through at least 2034 [1].

When does Exparel's patent expire?

Exparel's primary patents are set to expire in 2034 [1]. This provides the manufacturer, Pacira BioSciences, with market exclusivity until that time.

Can biosimilars enter before patent expiry?

Exparel is a small molecule drug, not a biologic, so biosimilarity is not applicable. The relevant term for generic versions of small molecule drugs is "generic competition" [1]. Generic versions of Exparel cannot enter the market before its patent protections expire, unless a patent is successfully challenged or invalidated [1].

Who makes Exparel?

Exparel is manufactured by Pacira BioSciences, Inc. [1].

What is Exparel used for?

Exparel is a non-opioid local anesthetic used to provide post-surgical pain relief [1]. It is administered by a healthcare professional to the surgical site during or after surgery.